<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: In vitro studies point to a toxic effect of high <z:chebi fb="105" ids="17234">glucose</z:chebi> and non-esterified fatty acids on beta cells </plain></SENT>
<SENT sid="1" pm="."><plain>Whether elevated levels of <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipids</z:chebi> induce beta cell loss in vivo is less clear </plain></SENT>
<SENT sid="2" pm="."><plain>The domestic cat has recently been proposed as a valuable animal model for human type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> because feline <z:mp ids='MP_0002055'>diabetes</z:mp> shows several similarities with <z:mp ids='MP_0002055'>diabetes</z:mp> in humans, including <z:hpo ids='HP_0001513'>obesity</z:hpo>-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, impaired beta cell function, decreased number of beta cells and pancreatic <z:mpath ids='MPATH_34'>amyloid deposition</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We infused healthy cats with <z:chebi fb="105" ids="17234">glucose</z:chebi> or <z:chebi fb="23" ids="18059">lipids</z:chebi> for 10 days to clamp their blood concentrations at the approximate level found in untreated feline <z:mp ids='MP_0002055'>diabetes</z:mp> (<z:chebi fb="105" ids="17234">glucose</z:chebi>: 25-30 mmol/l; <z:chebi fb="0" ids="17855">triacylglycerols</z:chebi>: 3-7 mmol/l) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="105" ids="17234">Glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> levels were adequately targeted </plain></SENT>
<SENT sid="5" pm="."><plain>Plasma non-esterified fatty acids were increased by <z:chebi fb="23" ids="18059">lipid</z:chebi> infusion 1.7-fold </plain></SENT>
<SENT sid="6" pm="."><plain>A dramatic and progressive decline of plasma insulin levels was observed in <z:chebi fb="105" ids="17234">glucose</z:chebi>-infused cats beginning after 2 days of hyperglycaemic clamp </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, plasma insulin concentration and <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test were not affected by <z:e sem="disease" ids="C0020473" disease_type="Disease or Syndrome" abbrv="">hyperlipidaemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Compared with controls, <z:chebi fb="105" ids="17234">glucose</z:chebi>-infused cats had a 50% decrease in beta cells per pancreatic area </plain></SENT>
<SENT sid="9" pm="."><plain>Apoptotic islet cells and cleaved caspase-3-positive beta cells were observed in <z:chebi fb="105" ids="17234">glucose</z:chebi>-infused cats only </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: Sustained <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> but not <z:e sem="disease" ids="C0020473" disease_type="Disease or Syndrome" abbrv="">hyperlipidaemia</z:e> induces early and severe <z:hpo ids='HP_0006279'>beta cell dysfunction</z:hpo> in cats, and excess <z:chebi fb="105" ids="17234">glucose</z:chebi> causes beta cell loss via <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in vivo </plain></SENT>
<SENT sid="11" pm="."><plain>Hyperglycaemic clamps in cats may provide a good model to study the pathogenesis of <z:chebi fb="105" ids="17234">glucose</z:chebi> toxicity in beta cells </plain></SENT>
</text></document>